ReviewFrontiers in nephrology2025
The potential of neutrophil gelatinase-associated lipocalin in management of acute kidney injury and peritoneal dialysis-related peritonitis: a narrative review.
Review in Frontiers in nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophil gelatinase-associated lipocalin (NGAL) is a biomarker extensively studied in multiple diseases. While its application in chronic kidney disease (CKD) and kidney transplant patients is relatively limited, NGAL has shown significant promise in the early detection and diagnosis of acute kidney injury (AKI), which may improve more timely management and potentially better clinical outcomes. In addition, NGAL has demonstrated promising utility in identifying peritoneal dialysis-related peritonitis (PDRP) and monitoring the treatment response. This review aims to provide an in-depth overview of the available research findings of NGAL in the management of AKI and PDRP, having these two conditions discussed together is particularly important for nephrologists who manage both conditions, especially to explore the potential of more specific NGAL forms, such as monomer NGAL and homodimer NGAL, to enhance early diagnosis and effective management of AKI and PDRP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.